Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies

Pillaiyar Thanigaimalai, Sho Konno, Takehito Yamamoto, Yuji Koiwai, Akihiro Taguchi, Kentaro Takayama, Fumika Yakushiji, Kenichi Akaji, Shen En Chen, Aurash Naser-Tavakolian, Arne Schön, Ernesto I Freire, Yoshio Hayashi

Research output: Contribution to journalArticle

Abstract

We report the design and synthesis of a series of dipeptide-type inhibitors with novel P3 scaffolds that display potent inhibitory activity against SARS-CoV 3CLpro. A docking study involving binding between the dipeptidic lead compound 4 and 3CLpro suggested the modification of a structurally flexible P3 N-(3-methoxyphenyl)glycine with various rigid P3 moieties in 4. The modifications led to the identification of several potent derivatives, including 5c-k and 5n with the inhibitory activities (Ki or IC50) in the submicromolar to nanomolar range. Compound 5h, in particular, displayed the most potent inhibitory activity, with a Ki value of 0.006 μM. This potency was 65-fold higher than the potency of the lead compound 4 (Ki = 0.39 μM). In addition, the Ki value of 5h was in very good agreement with the binding affinity (16 nM) observed in isothermal titration calorimetry (ITC). A SAR study around the P3 group in the lead 4 led to the identification of a rigid indole-2-carbonyl unit as one of the best P3 moieties (5c). Further optimization showed that a methoxy substitution at the 4-position on the indole unit was highly favorable for enhancing the inhibitory potency.

Original languageEnglish (US)
Pages (from-to)372-384
Number of pages13
JournalEuropean Journal of Medicinal Chemistry
Volume68
DOIs
StatePublished - 2013

Fingerprint

SARS Virus
Lead compounds
Dipeptides
Protease Inhibitors
Scaffolds
Calorimetry
Titration
Glycine
Substitution reactions
Display devices
Derivatives
Inhibitory Concentration 50
indole
Lead

Keywords

  • Cysteine protease inhibitors
  • Dipeptide
  • Peptidomimetics
  • SARS

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds : Design, synthesis, biological evaluation, and docking studies. / Thanigaimalai, Pillaiyar; Konno, Sho; Yamamoto, Takehito; Koiwai, Yuji; Taguchi, Akihiro; Takayama, Kentaro; Yakushiji, Fumika; Akaji, Kenichi; Chen, Shen En; Naser-Tavakolian, Aurash; Schön, Arne; Freire, Ernesto I; Hayashi, Yoshio.

In: European Journal of Medicinal Chemistry, Vol. 68, 2013, p. 372-384.

Research output: Contribution to journalArticle

Thanigaimalai, P, Konno, S, Yamamoto, T, Koiwai, Y, Taguchi, A, Takayama, K, Yakushiji, F, Akaji, K, Chen, SE, Naser-Tavakolian, A, Schön, A, Freire, EI & Hayashi, Y 2013, 'Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies', European Journal of Medicinal Chemistry, vol. 68, pp. 372-384. https://doi.org/10.1016/j.ejmech.2013.07.037
Thanigaimalai, Pillaiyar ; Konno, Sho ; Yamamoto, Takehito ; Koiwai, Yuji ; Taguchi, Akihiro ; Takayama, Kentaro ; Yakushiji, Fumika ; Akaji, Kenichi ; Chen, Shen En ; Naser-Tavakolian, Aurash ; Schön, Arne ; Freire, Ernesto I ; Hayashi, Yoshio. / Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds : Design, synthesis, biological evaluation, and docking studies. In: European Journal of Medicinal Chemistry. 2013 ; Vol. 68. pp. 372-384.
@article{3de1ea7030d344a88284758996a1c08f,
title = "Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies",
abstract = "We report the design and synthesis of a series of dipeptide-type inhibitors with novel P3 scaffolds that display potent inhibitory activity against SARS-CoV 3CLpro. A docking study involving binding between the dipeptidic lead compound 4 and 3CLpro suggested the modification of a structurally flexible P3 N-(3-methoxyphenyl)glycine with various rigid P3 moieties in 4. The modifications led to the identification of several potent derivatives, including 5c-k and 5n with the inhibitory activities (Ki or IC50) in the submicromolar to nanomolar range. Compound 5h, in particular, displayed the most potent inhibitory activity, with a Ki value of 0.006 μM. This potency was 65-fold higher than the potency of the lead compound 4 (Ki = 0.39 μM). In addition, the Ki value of 5h was in very good agreement with the binding affinity (16 nM) observed in isothermal titration calorimetry (ITC). A SAR study around the P3 group in the lead 4 led to the identification of a rigid indole-2-carbonyl unit as one of the best P3 moieties (5c). Further optimization showed that a methoxy substitution at the 4-position on the indole unit was highly favorable for enhancing the inhibitory potency.",
keywords = "Cysteine protease inhibitors, Dipeptide, Peptidomimetics, SARS",
author = "Pillaiyar Thanigaimalai and Sho Konno and Takehito Yamamoto and Yuji Koiwai and Akihiro Taguchi and Kentaro Takayama and Fumika Yakushiji and Kenichi Akaji and Chen, {Shen En} and Aurash Naser-Tavakolian and Arne Sch{\"o}n and Freire, {Ernesto I} and Yoshio Hayashi",
year = "2013",
doi = "10.1016/j.ejmech.2013.07.037",
language = "English (US)",
volume = "68",
pages = "372--384",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds

T2 - Design, synthesis, biological evaluation, and docking studies

AU - Thanigaimalai, Pillaiyar

AU - Konno, Sho

AU - Yamamoto, Takehito

AU - Koiwai, Yuji

AU - Taguchi, Akihiro

AU - Takayama, Kentaro

AU - Yakushiji, Fumika

AU - Akaji, Kenichi

AU - Chen, Shen En

AU - Naser-Tavakolian, Aurash

AU - Schön, Arne

AU - Freire, Ernesto I

AU - Hayashi, Yoshio

PY - 2013

Y1 - 2013

N2 - We report the design and synthesis of a series of dipeptide-type inhibitors with novel P3 scaffolds that display potent inhibitory activity against SARS-CoV 3CLpro. A docking study involving binding between the dipeptidic lead compound 4 and 3CLpro suggested the modification of a structurally flexible P3 N-(3-methoxyphenyl)glycine with various rigid P3 moieties in 4. The modifications led to the identification of several potent derivatives, including 5c-k and 5n with the inhibitory activities (Ki or IC50) in the submicromolar to nanomolar range. Compound 5h, in particular, displayed the most potent inhibitory activity, with a Ki value of 0.006 μM. This potency was 65-fold higher than the potency of the lead compound 4 (Ki = 0.39 μM). In addition, the Ki value of 5h was in very good agreement with the binding affinity (16 nM) observed in isothermal titration calorimetry (ITC). A SAR study around the P3 group in the lead 4 led to the identification of a rigid indole-2-carbonyl unit as one of the best P3 moieties (5c). Further optimization showed that a methoxy substitution at the 4-position on the indole unit was highly favorable for enhancing the inhibitory potency.

AB - We report the design and synthesis of a series of dipeptide-type inhibitors with novel P3 scaffolds that display potent inhibitory activity against SARS-CoV 3CLpro. A docking study involving binding between the dipeptidic lead compound 4 and 3CLpro suggested the modification of a structurally flexible P3 N-(3-methoxyphenyl)glycine with various rigid P3 moieties in 4. The modifications led to the identification of several potent derivatives, including 5c-k and 5n with the inhibitory activities (Ki or IC50) in the submicromolar to nanomolar range. Compound 5h, in particular, displayed the most potent inhibitory activity, with a Ki value of 0.006 μM. This potency was 65-fold higher than the potency of the lead compound 4 (Ki = 0.39 μM). In addition, the Ki value of 5h was in very good agreement with the binding affinity (16 nM) observed in isothermal titration calorimetry (ITC). A SAR study around the P3 group in the lead 4 led to the identification of a rigid indole-2-carbonyl unit as one of the best P3 moieties (5c). Further optimization showed that a methoxy substitution at the 4-position on the indole unit was highly favorable for enhancing the inhibitory potency.

KW - Cysteine protease inhibitors

KW - Dipeptide

KW - Peptidomimetics

KW - SARS

UR - http://www.scopus.com/inward/record.url?scp=84882798645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882798645&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2013.07.037

DO - 10.1016/j.ejmech.2013.07.037

M3 - Article

C2 - 23994330

AN - SCOPUS:84882798645

VL - 68

SP - 372

EP - 384

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -